The Development of Biomarkers in Lung Cancer

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, comments on the development of biomarkers for lung cancer.

Clinical Pearls

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, comments on the development of biomarkers for lung cancer.

  • Every tumor has a different driver. The point has been reached where combinations seem to be future.
  • Developing appropriate drug combinations is challenging, partly because of toxicity.
  • There remains a need to further understand tumor biology to target it more specifically.